Amgen, Inc. (AMGN) Position Raised by Davis R M Inc.

Davis R M Inc. increased its stake in Amgen, Inc. (NASDAQ:AMGN) by 12.3% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 6,164 shares of the medical research company’s stock after acquiring an additional 677 shares during the quarter. Davis R M Inc.’s holdings in Amgen were worth $1,149,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in AMGN. FMR LLC lifted its position in Amgen by 4.8% in the second quarter. FMR LLC now owns 56,999,572 shares of the medical research company’s stock valued at $9,817,037,000 after buying an additional 2,587,041 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Amgen by 0.9% during the second quarter. Vanguard Group Inc. now owns 52,146,935 shares of the medical research company’s stock worth $8,981,266,000 after purchasing an additional 489,720 shares in the last quarter. BlackRock Inc. lifted its position in shares of Amgen by 1.9% during the second quarter. BlackRock Inc. now owns 49,451,203 shares of the medical research company’s stock worth $8,516,980,000 after purchasing an additional 909,689 shares in the last quarter. Nordea Investment Management AB increased its stake in shares of Amgen by 12.9% during the second quarter. Nordea Investment Management AB now owns 7,040,599 shares of the medical research company’s stock worth $1,212,602,000 after buying an additional 806,119 shares during the period. Finally, The Manufacturers Life Insurance Company increased its stake in shares of Amgen by 3.1% during the second quarter. The Manufacturers Life Insurance Company now owns 3,968,892 shares of the medical research company’s stock worth $683,562,000 after buying an additional 121,202 shares during the period. 78.46% of the stock is owned by institutional investors and hedge funds.

Amgen, Inc. (NASDAQ:AMGN) opened at $176.42 on Monday. The company has a debt-to-equity ratio of 1.05, a quick ratio of 5.72 and a current ratio of 6.07. The company has a market capitalization of $128,070.00, a PE ratio of 15.94, a PEG ratio of 2.56 and a beta of 1.36. Amgen, Inc. has a fifty-two week low of $145.62 and a fifty-two week high of $191.10.

Amgen (NASDAQ:AMGN) last announced its earnings results on Wednesday, October 25th. The medical research company reported $3.27 earnings per share for the quarter, beating the consensus estimate of $3.11 by $0.16. Amgen had a return on equity of 29.90% and a net margin of 35.54%. The firm had revenue of $5.77 billion during the quarter, compared to the consensus estimate of $5.75 billion. During the same quarter in the prior year, the company earned $3.02 EPS. The firm’s revenue for the quarter was down .7% compared to the same quarter last year. analysts expect that Amgen, Inc. will post 12.67 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 8th. Investors of record on Thursday, February 15th will be given a dividend of $1.32 per share. This represents a $5.28 annualized dividend and a dividend yield of 2.99%. The ex-dividend date of this dividend is Wednesday, February 14th. This is an increase from Amgen’s previous quarterly dividend of $1.15. Amgen’s dividend payout ratio (DPR) is 41.55%.

Amgen declared that its board has authorized a stock buyback program on Wednesday, October 25th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the medical research company to purchase shares of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s management believes its stock is undervalued.

Several brokerages have commented on AMGN. Mizuho set a $192.00 price target on shares of Amgen and gave the company a “buy” rating in a research note on Friday. BMO Capital Markets reaffirmed a “hold” rating and set a $199.00 price target on shares of Amgen in a report on Monday, September 25th. Credit Suisse Group reaffirmed a “neutral” rating and set a $186.00 price target (up from $177.00) on shares of Amgen in a report on Friday, September 29th. Oppenheimer set a $205.00 target price on Amgen and gave the company a “buy” rating in a report on Tuesday, December 12th. Finally, Cann reissued a “buy” rating and issued a $205.00 target price on shares of Amgen in a report on Thursday, November 30th. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $189.94.

In other news, Director Carbonnel Francois De sold 4,000 shares of the firm’s stock in a transaction on Wednesday, November 8th. The stock was sold at an average price of $173.61, for a total value of $694,440.00. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Sean E. Harper sold 1,525 shares of the firm’s stock in a transaction on Monday, October 9th. The stock was sold at an average price of $185.95, for a total value of $283,573.75. The disclosure for this sale can be found here. Insiders have sold a total of 8,575 shares of company stock valued at $1,509,339 over the last ninety days. Insiders own 0.19% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was reported by Community Financial News and is the property of of Community Financial News. If you are reading this report on another website, it was illegally stolen and republished in violation of U.S. & international copyright law. The correct version of this report can be read at https://www.com-unik.info/2017/12/25/amgen-inc-amgn-position-raised-by-davis-r-m-inc.html.

Amgen Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit